UNSPSC 51434305: Torasemide

This classification denotes a loop diuretic with the molecular formula C16H20N4O3S, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier W31X2H97FB, chemically known as 3-pyridinesulfonamide, n-(((1-methylethyl)amino)carbonyl)-4-((3-methylphenyl)amino)- but more generally known as torasemide, which bears U.S. National Institutes of Health Compound Identifier 41781. European Medicines Agency schedules Torasemide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11195MIG.

UNSPSC 51434305 Torasemide, a Commodity code, encompasses pharmaceutical products—specifically loop diuretics and related medications—that state and local governments procure for emergency medical services, public health agencies, and cooperative purchasing arrangements. State and local buyers under this code acquire individual medication line items in bulk quantities for use by fire rescue services, EMS systems, and multistate purchasing consortia. The issuing bodies span city fire departments, state health and human services commissions, and cooperative purchasing alliances serving multiple state and local jurisdictions. Recent solicitations show that state and local procurement under this code focuses on direct supply of branded and generic pharmaceuticals meeting FDA compliance, cGMP certification, Drug Supply Chain Security Act (DSCSA) compliance, and expiration-date requirements, with vendors often required to work through authorized wholesalers or to arrange direct delivery to end-user facilities.

Activity under this code spans Florida, Texas, and Minnesota through multistate arrangements. The City of Tampa's Purchasing Department issued IFB 26P00188 on April 24, 2026 (due April 8, 2026) for Advanced Life Support Medications including Labetalol, Epinephrine, Adenosine, and Diltiazem for Tampa Fire Rescue, with an estimated contract value of $40,000, a one-year term plus two optional one-year renewals, and SLBE sheltered market designation at a 5 percent bid discount not to exceed $10,000. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, with awards effective July 1, 2026 and a two-year term. The Texas Health and Human Services Commission issued RFI HHS0017013 in late March 2026 to gather market intelligence on direct-to-manufacturer prescription programs, signaling early-stage procurement development for pharmacy benefit programs outside traditional PBM and GPO channels.